Shots:
The US FDA has cleared Edesa Biotech’s IND application for its P-II study of EB06 in vitiligo, enabling expansion of recruitment to the US; recruitment is underway in Canada, with the first US sites expected to begin enrolling next quarter and topline data anticipated in Q4’27
The double-blind, PBO-controlled study is evaluating EB06 vs…
